This meeting draws together international experts to discuss current techniques and research involved in cellular and molecular pathology.

With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding pathology.  This meeting gathers together workings from clinical, academic and pharmaceutical organisations.

A late registration fee applies after Oct 20th 2015

This event has an open abstract session.

This event has CPD accreditation

Who Should Attend

All who need to be at the leading edge of developments in this area will find this attendance at this conference rewarding.  Attendance is recommended to both professionals and students within the diagnostic and research communities that engage with pathology.

Talks include:

• Functional role of microRNAs in alcoholic liver diseases:

 Dr Fanyin Meng, Assistant Professor, Digestive Disease Research Center, Scott & White Hospital, Texas A&M HSC College of Medicine,Texas, US

• Aging-associated fiber-specific muscle atrophy is marked with  novel Proteasome activity probes:

 Dr Vered Raz, Department of Human Genetics, Leiden University Medical Centre, Leiden, Netherlands

• Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis:

 Professor Gail Risbridger, Monash University, Research Director, Monash Partners Comprehensive Cancer Consortium (MpCCC), Victoria, Australia

• The clinical value of epigenetics in breast cancer:

 Olafur Andri Stefansson, University of Iceland, Iceland

• Diagnostic dilemmas in lupus anticoagulant detection:

 Dr Gary Moore, Consultant Biomedical Scientist, Head of Diagnostic Haemostasis & Thrombosis Laboratory, London, UK

• Role of IKK alpha in predicting recurrence in ER positive breast cancer:

 Dr Joanne Edwards BSc, PhD, FRCPath, Senior Lecturer, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, Scotland, UK

• Cardiovascular pathology from tobacco smoke:  

Dr Aurelio Leone, Independent Researcher, Magra(sp), Italy

• Traumatic brain injuries and diffuse axonal injuries – translation between experimental models and clinical practise:  

Professor Mårten Risling, Karolinska institutet, Stockholm, Sweden

• Mitochondriome and Cholangiocellular Carcinoma:  

Professor Consolato Maria Sergi, Department of Lab. Medicine and Pathology, University of Alberta, Canada

• Dematitis herpetiformis is, first and foremost, a cutaneous disease:

 Professor Marian Dmochowski, Autoimmune Blistering Dermatoses Section, Dermatology, Poznan University of Medical Sciences

• Cortical minicolumn: from executive control to executive dysfunction:

 Dr Ioan Opris, Wake forest university school of medicine, North Carolina, USA

• The aneuploidy paradox in maligant tumours: let us consider parasexual processes:

 Dr.H.MJekaterina Erenpreisa, Latvian Biomedical Research & Study Centre, Riga, Latvia

• Tissue Pathology and Pathways in Chronic Human Lymphatic Insufficiency:

 Dr Stanley G. Rockson, Stanford University School of Medicine ,  Stanford, CA, USA

• New Decalcification Methods Applied to Bone and Teeth Tissues using Nanomaterials:

 Dr. Gerardo Rivera Silva, University of Monterrey, NL, MEXICO

• Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections:

 Ms Roslyn Lloyd, Quantitative Pathology Applications, PerkinElmer, USA

• Early cancer detection:

 Professor Ian A Cree, Yvonne Carter Professor of Pathology, Warwick Medical School, Clinical Sciences Building, University Hospitals Coventry and Warwickshire, London, UK

• Endothelial dysfunction in diabetic heart; from phenotypic changes to associated molecules:  

Dr Doina Popovm, Member of the Romanian Academy “Pathophysiology and Pharmacology” Department Institute of Cellular Biology and Pathology

• An actionable molecular test as cost-effective risk predictor of oral cancer progression:

 Dr Catherine Poh, University of Bristish Columbia, BC Cancer Agency, Columbia

• Targeting PPARbeta/delta in lung disease:

Dr Louise Mackenzie, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom

                          

 

 

 

 

 

Sponsors

#Path2015 Tweets